Coll, Anthony P.
Chen, Michael
Taskar, Pranali
Rimmington, Debra
Patel, Satish
Tadross, John A.
Cimino, Irene
Yang, Ming
Welsh, Paul
Virtue, Samuel
Goldspink, Deborah A.
Miedzybrodzka, Emily L.
Konopka, Adam R.
Esponda, Raul Ruiz
Huang, Jeffrey T.-J.
Tung, Y. C. Loraine
Rodriguez-Cuenca, Sergio
Tomaz, Rute A.
Harding, Heather P.
Melvin, Audrey
Yeo, Giles S. H.
Preiss, David
Vidal-Puig, Antonio
Vallier, Ludovic
Nair, K. Sreekumaran
Wareham, Nicholas J.
Ron, David
Gribble, Fiona M.
Reimann, Frank
Sattar, Naveed
Savage, David B.
Allan, Bernard B.
O’Rahilly, Stephen
Article History
Received: 1 July 2019
Accepted: 16 December 2019
First Online: 25 December 2019
Change Date: 13 February 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-020-2031-4
Competing interests
: P.W. has received grant support from Roche Diagnostics, AstraZeneca and Boehringer Ingelheim. N.S. has consulted for AstraZeneca, Boehringer Ingelheim, Eli Lilly, Napp, Novo Nordisk and Sanofi, and received grant support from Boehringer Ingelheim. M.C., P.T. and B.B.A. are or were employees of NGM Biopharmaceuticals and may hold NGM stock or stock options. F.R. and F.M.G. have received support from AstraZeneca and Eli Lilly. F.M.G. has provided remunerated consultancy services to Kallyope. S.O. has provided remunerated consultancy services to Pfizer, AstraZeneca, Novo-Nordisk and ERX Pharmaceuticals. All other authors declare no competing interests.